๐ข ๐๐จ๐ฆ๐ง ๐๐ก: Novo Nordisk Raises 2026 Outlook on Stronger GLP-1 Sales Expectations - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐ก๐ผ๐๐ผ ๐ก๐ผ๐ฟ๐ฑ๐ถ๐๐ธ raised its full-year ๐ฎ๐ฌ๐ฎ๐ฒ adjusted guidance.โค Higher outlook reflects stronger expected ๐๐๐ฃ-๐ญ product sales.โค Adjusted sales guidance improved to ๐ฌ% ๐๐ผ -๐ฒ% at CER.โค Previous adjusted sales outlook was -๐ฐ% ๐๐ผ -๐ญ๐ฎ% at CER.โค Adjusted operating profit guidance improved to ๐ฌ% ๐๐ผ -๐ฒ% at CER.โค ๐ค๐ฎ adjusted sales reached ๐๐๐ ๐ณ๐ด,๐ฐ๐ด๐ด ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, up ๐ณ% at CER.โค ๐ค๐ฎ adjusted operating profit totaled ๐๐๐ ๐ฏ๐ฏ,๐ฏ๐ด๐ต ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, up ๐ญ๐ญ% at CER.โค Results exclude one-time impacts from the U.S. ๐ฏ๐ฐ๐ฌ๐ ๐๐ฟ๐๐ด ๐ฃ๐ฟ๐ถ๐ฐ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ผ๐ด๐ฟ๐ฎ๐บ.โค ๐ค๐ฎ included ๐๐๐ ๐ฒ.๐ฏ ๐ฏ๐ถ๐น๐น๐ถ๐ผ๐ป in non-cash impairment charges.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Improved guidance signals stronger-than-expected demand for ๐๐๐ฃ-๐ญ therapies.โค Higher outlook may strengthen investor confidence in Novo Nordisk's earnings trajectory.โค Excluding one-time items provides a clearer view of underlying operating performance.
NVO251121C40000.US
NVO251121C40000----
Share your thoughts
Write something you'd like to share with our community...
0 / 2,000
- L
[Giveaway] Claude Now Connects to Longbridge: 140+ Tools in Chat, Free Real-Time US & HK Data
Claude now connects to Longbridge โ free real-time US & HK data, 140+ tools in chat. Share your first question to win.
+6
ๆดๆฐๅจๆ - F
โข The Nasdaq composite and AI chip stocks experienced a rally despite $Apple(AAPL.US)'s decline.
โข Microsoft and Amazon reported strong earnings, highlighting concerns over AI spending. โข Sezzle, a fintech stock, surged 144% this year and is rebounding. $Sezzle(SEZL.US) โข NB Bancorp stock broke out past a new buy point amid market weakness. โข U.S. oil output and exports are at high levels, with the SPR at a 43-year low. โข Novo Nordisk and Eli Lilly faced selling pressure in the weight loss drug sector. $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US) โข IES Holdings stock rose 31% following a positive outlook for AI data centers. - H
๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $Novo Nordisk AS(NVO.US) Novo Nordisk's Phase 3 Ziltivekimab Trial Misses Primary Cardiovascular Endpoint
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐ก๐ผ๐๐ผ ๐ก๐ผ๐ฟ๐ฑ๐ถ๐๐ธ's ๐ญ๐๐จ๐ฆ phase 3 trial failed to reduce ๐ ๐๐๐.โค Hazard ratio was ๐ฌ.๐ต๐ต with a ๐ต๐ฑ% confidence interval of ๐ฌ.๐ด๐ดโ๐ญ.๐ญ๐ญ.โค Trial enrolled more than ๐ฒ,๐ฏ๐ฌ๐ฌ patients with ๐๐ฆ๐๐ฉ๐, ๐๐๐, and elevated inflammation.โค Ziltivekimab reduced ๐๐-๐ฒ and ๐ต๐๐๐ฅ๐ฃ, confirming target engagement.โค Biological improvements did not translate into fewer cardiovascular events.โค Serious infections occurred more frequently with ๐๐ถ๐น๐๐ถ๐๐ฒ๐ธ๐ถ๐บ๐ฎ๐ฏ than placebo.โค No difference in ๐ฎ๐น๐น-๐ฐ๐ฎ๐๐๐ฒ ๐บ๐ผ๐ฟ๐๐ฎ๐น๐ถ๐๐ was observed.โค Novo Nordisk expects a ๐ป๐ผ๐ป-๐ฐ๐ฎ๐๐ต impairment charge in ๐ค๐ฏ ๐ฎ๐ฌ๐ฎ๐ฒ.โค ๐๐๐ฅ๐ ๐๐ฆ and ๐๐ฅ๐ง๐๐ ๐๐ฆ phase 3 trials will continue, with results expected in ๐๐ญ ๐ฎ๐ฌ๐ฎ๐ณ.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Represents a setback for Novo Nordisk's ๐ฐ๐ฎ๐ฟ๐ฑ๐ถ๐ผ๐๐ฎ๐๐ฐ๐๐น๐ฎ๐ฟ drug pipeline.โค Raises questions about whether ๐๐-๐ฒ inhibition alone improves cardiovascular outcomes.โค May shift investor focus toward upcoming ๐๐๐ฅ๐ ๐๐ฆ and ๐๐ฅ๐ง๐๐ ๐๐ฆ trial results.โค Company says ๐ฎ๐ฌ๐ฎ๐ฒ operating profit guidance remains unchanged.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐ ๐ฎ๐ฟ๐๐ถ๐ป ๐๐ผ๐น๐๐ ๐๐ฎ๐ป๐ด๐ฒ, Executive Vice President and Chief Scientific Officer at Novo Nordisk:"Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population." - H
๐ข ๐๐จ๐ฆ๐ง ๐๐ก: Eli Lilly Delays Retatrutide Approval Filing to Q1 2027 - $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US)
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐๐น๐ถ ๐๐ถ๐น๐น๐ plans to file for ๐ฟ๐ฒ๐๐ฎ๐๐ฟ๐๐๐ถ๐ฑ๐ฒ approval in ๐ค๐ญ ๐ฎ๐ฌ๐ฎ๐ณ.โค Filing delayed to gather additional ๐บ๐ฎ๐ป๐๐ณ๐ฎ๐ฐ๐๐๐ฟ๐ถ๐ป๐ด and quality-control data.โค Phase 3 trials met primary endpoints in two additional studies.โค Adults with obesity and Type 2 diabetes lost up to ๐ฎ๐ป ๐ฎ๐๐ฒ๐ฟ๐ฎ๐ด๐ฒ ๐ผ๐ณ ๐ฎ๐ฌ.๐ด% body weight.โค Adults with severe obesity and cardiovascular disease lost up to ๐ฎ๐ป ๐ฎ๐๐ฒ๐ฟ๐ฎ๐ด๐ฒ ๐ผ๐ณ ๐ฎ๐ฎ.๐ฒ% body weight.โค Retatrutide targets ๐๐๐ฃ-๐ญ, ๐๐๐ฃ, and ๐ด๐น๐๐ฐ๐ฎ๐ด๐ผ๐ป hormones.โค Common side effects included ๐ฑ๐ถ๐ฎ๐ฟ๐ฟ๐ต๐ฒ๐ฎ, ๐ป๐ฎ๐๐๐ฒ๐ฎ, and ๐ฐ๐ผ๐ป๐๐๐ถ๐ฝ๐ฎ๐๐ถ๐ผ๐ป.โค TD Cowen estimates retatrutide could generate $๐ฏ.๐ด ๐ฏ๐ถ๐น๐น๐ถ๐ผ๐ป in ๐ฎ๐ฌ๐ฏ๐ฌ sales.โค Novo Nordisk recently sued Lilly over ๐ฎ๐น๐น๐ฒ๐ด๐ฒ๐ฑ false advertising claims.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐๐ฒ๐ป๐ป๐ฒ๐๐ต ๐๐๐๐๐ฒ๐ฟ, President of Lilly Cardiometabolic Health:"We believe we have the information necessary to file for approval globally for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnea." - H
๐ข ๐๐๐๐ ๐๐: Novo Nordisk Sues Eli Lilly in U.S. Federal Court, Alleging Claim Under the Lanham Act, Court Records Show - $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US)
- M
Novo Nordisk remains a world-class company with leading diabetes and obesity treatments, but I'm re-evaluating my investment. Competition in the obesity market is intensifying, and future growth may become less predictable. I may eventually switch to a healthcare company with a more diversified business and lower execution risk while continuing to monitor Novo Nordisk's progress.
Trade Showcase: Trade, Show & Earn Rewards! - H
๐ข ๐๐๐๐ ๐๐: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐ฎ๐ซ๐จ๐ฉ๐๐๐ง ๐๐จ๐ฆ๐ฆ๐ข๐ฌ๐ฌ๐ข๐จ๐ง approves ๐จ๐ซ๐๐ฅ ๐๐๐ ๐จ๐ฏ๐ฒ ๐๐ ๐ฆ๐ .โค Approval covers adults with ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ or overweight with comorbidities.โค Oral Wegovy becomes Novo Nordisk's ๐๐ข๐๐ญ๐ก regulatory approval globally.โค OASIS 4 trial showed approximately ๐๐% mean weight loss over 64 weeks.โค Placebo group recorded approximately ๐๐% mean weight loss.โค Around ๐จ๐ง๐ ๐ข๐ง ๐ญ๐ก๐ซ๐๐ participants lost ๐๐๐% or more body weight.โค EU also approved ๐๐๐ ๐จ๐ฏ๐ฒ ๐.๐ ๐ฆ๐ single-dose injection pen.โค Novo Nordisk says the injection delivers approximately ๐๐๐% weight loss.โค Company plans additional global launches in ๐ญ๐ก๐ ๐ฌ๐๐๐จ๐ง๐ ๐ก๐๐ฅ๐ ๐จ๐ ๐๐๐๐.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ:๐๐ข๐ค๐ ๐๐จ๐ฎ๐ฌ๐ญ๐๐๐ซ, president and CEO of Novo Nordisk:"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment." - H
$Hims & Hers Health(HIMS.US) | Canaccord maintains ๐๐ฎ๐ฒ on ๐๐ข๐ฆ๐ฌ & ๐๐๐ซ๐ฌ, ๐ซ๐๐ข๐ฌ๐๐ฌ ๐๐ ๐ญ๐จ $๐๐ ๐๐ซ๐จ๐ฆ $๐๐
Analyst highlights a solid start to branded weight loss drugs, constructive sales data, and sees Hims as one of Novo's most "voluminous" partners. - H
๐ข ๐๐๐๐ ๐๐: Eli Lilly Plans Europe Launch of Weight-Loss Pill in Late 2026 or Early 2027 - $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค ๐๐ฅ๐ข ๐๐ข๐ฅ๐ฅ๐ฒ plans to launch its weight-loss pill in Europe and Britain in ๐๐ ๐๐๐๐ or early ๐๐๐๐.โค Launch timing depends on obtaining ๐ซ๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ approvals across target markets.โค Lilly will initially target the ๐จ๐ฎ๐ญ-๐จ๐-๐ฉ๐จ๐๐ค๐๐ญ telehealth market.โค Strategy mirrors Lilly's ๐.๐. direct-to-consumer obesity business model.โค The company plans partnerships with ๐ญ๐๐ฅ๐๐ก๐๐๐ฅ๐ญ๐ก providers and digital health platforms.โค Lilly says obesity treatment outside the U.S. is largely ๐ฉ๐๐ญ๐ข๐๐ง๐ญ-๐ฉ๐๐ข๐.โค The drug recently secured approvals in the ๐.๐. and ๐๐๐.โค Lilly will continue pursuing ๐ ๐จ๐ฏ๐๐ซ๐ง๐ฆ๐๐ง๐ญ reimbursement where available.โค U.S. ๐ฆ๐จ๐ฌ๐ญ-๐๐๐ฏ๐จ๐ฎ๐ซ๐๐-๐ง๐๐ญ๐ข๐จ๐ง pricing policies may affect negotiations.๐ ๐๐ก๐ฒ ๐๐ญ ๐๐๐ญ๐ญ๐๐ซ๐ฌ:โค Expands Lilly's presence in the rapidly growing ๐ ๐ฅ๐จ๐๐๐ฅ obesity treatment market.โค Telehealth-focused distribution could accelerate ๐ฉ๐๐ญ๐ข๐๐ง๐ญ access and adoption.โค European expansion may create a significant new ๐ซ๐๐ฏ๐๐ง๐ฎ๐ opportunity for Lilly.๐ ๐๐ฑ๐ฉ๐๐ซ๐ญ ๐๐ญ๐๐ญ๐๐ฆ๐๐ง๐ญ:โค "Our goal will still be public coverage, wherever possible." โ ๐๐๐ญ๐ซ๐ข๐ค ๐๐จ๐ง๐ฌ๐ฌ๐จ๐ง, Executive Vice President of Lilly's International Businesses.โค "MFN will play a role for all launches." โ ๐๐๐ญ๐ซ๐ข๐ค ๐๐จ๐ง๐ฌ๐ฌ๐จ๐ง. - F
Some stocks I think that are at insanely good valuation to start accumulation for the next few years.
- $Microsoft(MSFT.US) at 19 Forward P/E. Too good to ignore. PT: 600+ - $Salesforce(CRM.US) at sub 10 F.P/E. A generational opportunity? PT: 300+ - $ServiceNow(NOW.US) at 19 F.P/E and under 1 PEG. PT: 200+ - $Novo Nordisk AS(NVO.US) is yet another generational opportunity at 10 P/E. PT: 130+ - $Citigroup(C.US), even for a bank this is supremely cheap fundamentals. F.P/E at 11 and PEG under 0.5. PT: 200+ - $Toronto Dominion Bank(TD.US), one more bank and cheaper than remaining banks. PT: 150+ - $Adobe(ADBE.US) F.P/E 7 and PEG under 0.5. PT: 300+ There are a few more but I think you get the point. You have any ideas to share? - H
๐ข ๐๐๐๐ ๐๐: Novo Nordisk to Seek China Approval for Oral Wegovy Within Months - $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค Novo Nordisk plans to file for China approval of oral Wegovy within months.โค CEO Mike Doustdar announced the timeline during his first China visit as CEO.โค Oral weight-loss drugs target patients reluctant to use injections.โค Novo and Eli Lilly are competing for China's obesity treatment market.โค Lilly submitted a China marketing application for orforglipron in late 2025.โค China's semaglutide patent expired in March; data protection lasts until early 2027.โค Novo expects generic competition beginning in Q2 2027.โค Novo says large-scale manufacturing could be a key barrier for competitors.โค Oral Wegovy has secured approvals in the U.S. and U.K., with a U.S. launch underway.โค China GLP-1 sales reached about Yuan 1.4 billion ($207 million) in Q1. - H
๐ข ๐๐๐๐ ๐๐: Novo Nordisk's Wegovy Pill Approved in UK for Weight Management - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค UK approves ๐๐๐ ๐จ๐ฏ๐ฒ ๐ฉ๐ข๐ฅ๐ฅ, oral semaglutide for weight management.โค UK becomes ๐๐ฎ๐ซ๐จ๐ฉ๐'๐ฌ ๐๐ข๐ซ๐ฌ๐ญ country authorizing the treatment.โค Approved for adults with ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ or weight-related conditions.โค Medication to be used alongside ๐๐ข๐๐ญ and ๐๐ฑ๐๐ซ๐๐ข๐ฌ๐.โค Novo expects availability via ๐ฉ๐ซ๐ข๐ฏ๐๐ญ๐ ๐ฉ๐ซ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง within weeks.โค OASIS 4 trial: ๐๐ฉ๐ฉ๐ซ๐จ๐ฑ๐ข๐ฆ๐๐ญ๐๐ฅ๐ฒ ๐๐% weight loss versus 2% placebo.โค Treatment-adherent participants achieved ๐๐ฉ๐ฉ๐ซ๐จ๐ฑ๐ข๐ฆ๐๐ญ๐๐ฅ๐ฒ ๐๐% weight loss.โค Most common side effects were ๐ ๐๐ฌ๐ญ๐ซ๐จ๐ข๐ง๐ญ๐๐ฌ๐ญ๐ข๐ง๐๐ฅ symptoms.โค About ๐% discontinued treatment due to adverse events.โค Approval follows authorizations from ๐ ๐๐ and ๐๐๐ regulators. - H
๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐ Goldman Sachs lifts global obesity-drug forecast to $114bn by 2030 as oral GLP-1s go mainstream - $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US)
Goldman Sachs raised its forecast for the global obesity-drug market to $114bn by 2030, up roughly 13% from a $101bn projection in December, citing rapid adoption of oral GLP-1 obesity drugs and a shift from a niche, high-price segment to a mass-consumer market. - H
๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐: TD Cowen Raises Global ๐๐๐-๐ Market Forecast to $๐๐๐๐ by 2030 - $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค TD Cowen raises ๐๐๐-๐ market forecast to $๐๐๐๐ by ๐๐๐๐.โค Forecast increased from prior estimate of $๐๐๐๐.โค Expected patient population grows to ๐๐๐, up from ๐๐๐.โค Higher treatment volumes expected to offset ๐ฉ๐ซ๐ข๐๐ ๐ซ๐๐๐ฎ๐๐ญ๐ข๐จ๐ง๐ฌ.โค Oral GLP-1 therapies projected to reach ๐๐% of global sales.โค Forecast covers both ๐๐ฒ๐ฉ๐ ๐ ๐๐ข๐๐๐๐ญ๐๐ฌ and obesity treatments.โค Eli Lilly and Novo Nordisk expected to retain dominant ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐ก๐๐ซ๐๐ฌ. - H
$Novo Nordisk AS(NVO.US) | ๐๐จ๐ฅ๐๐ฆ๐๐ง ๐๐๐๐ก๐ฌ ๐ซ๐๐ข๐ฌ๐๐ฌ ๐๐ on ๐๐จ๐ฏ๐จ ๐๐จ๐ซ๐๐ข๐ฌ๐ค to $๐๐ from $๐๐, maintains ๐๐๐ฎ๐ญ๐ซ๐๐ฅ
- H
๐ข ๐๐๐๐ ๐๐: Novo Nordisk Uses AI to Cut Drug Filing Timelines by Up to Two-Thirds - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค Novo Nordisk leverages ๐๐ to accelerate drug development and approvals.โค Filing timelines reduced from ~๐๐ months to significantly fewer months.โค AI supports ๐ซ๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐๐จ๐๐ฎ๐ฆ๐๐ง๐ญ drafting and safety analysis.โค Bengaluru hub plays growing role in ๐ ๐ฅ๐จ๐๐๐ฅ ๐๐ซ๐ฎ๐ launches.โค Company used India center for recently launched ๐จ๐ซ๐๐ฅ ๐จ๐๐๐ฌ๐ข๐ญ๐ฒ pill rollout.โค AI-driven operations shifting hiring toward ๐ฌ๐ฉ๐๐๐ข๐๐ฅ๐ข๐ณ๐๐ ๐ซ๐จ๐ฅ๐๐ฌ over headcount growth.โค Industry forecasts see AI cutting early-stage development timelines by ๐๐%. - H
๐ข ๐๐๐๐ ๐๐: Eli Lilly Reports Strong Weight-Loss Data for Oral GLP-1 in Older Adults - $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค Eli Lilly presented new ๐ ๐จ๐ฎ๐ง๐๐๐ฒ๐จ (orforglipron) data at ๐๐๐ ๐๐๐๐.โค Oral GLP-1 showed up to ๐๐.๐% weight loss in adults ๐๐+.โค Results came from Phase ๐ ๐๐๐๐๐๐-๐ and ๐๐๐๐๐๐-๐ trials.โค Benefits observed in patients both with and without ๐ญ๐ฒ๐ฉ๐ ๐ ๐๐ข๐๐๐๐ญ๐๐ฌ.โค Foundayo is the only approved ๐จ๐ซ๐๐ฅ ๐๐๐-๐ without food or water restrictions.โค Most common side effects were ๐ ๐๐ฌ๐ญ๐ซ๐จ๐ข๐ง๐ญ๐๐ฌ๐ญ๐ข๐ง๐๐ฅ symptoms like nausea and diarrhea.โค Safety profile remained generally ๐๐จ๐ง๐ฌ๐ข๐ฌ๐ญ๐๐ง๐ญ across age groups. - H
๐ข ๐๐๐๐ ๐๐: Eli Lillyโs Retatrutide Shows Up to ๐๐.๐% Weight Loss in Phase 3 Trial - $Eli Lilly(LLY.US) $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US)
๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โค Lillyโs ๐ซ๐๐ญ๐๐ญ๐ซ๐ฎ๐ญ๐ข๐๐ achieved up to ๐๐.๐% weight loss over ๐๐ weeks.โค Highest ๐๐ ๐ฆ๐ dose delivered average loss of ๐๐.๐ pounds.โค ๐๐.๐% of participants lost ๐๐% or more body weight.โค Extension study showed up to ๐๐.๐% weight loss after ๐๐๐ weeks.โค ๐๐.๐% of patients on ๐๐ ๐ฆ๐ moved below obesity-level BMI.โค Common side effects included ๐ง๐๐ฎ๐ฌ๐๐, diarrhea, constipation, and vomiting.โค Retatrutide targets ๐๐๐, ๐๐๐-๐, and glucagon hormone receptors.